Septerna (NASDAQ:SEPN) Reaches New 12-Month High – Should You Buy?

Septerna, Inc. (NASDAQ:SEPN) reached a new 52-week high during trading on Friday . The company traded as high as $30.12 and last traded at $29.6750, with a volume of 135119 shares changing hands. The stock had previously closed at $27.54.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Raymond James Financial started coverage on Septerna in a research report on Friday. They set a “strong-buy” rating and a $38.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price objective on shares of Septerna in a research note on Friday, September 5th. Truist Financial initiated coverage on shares of Septerna in a research note on Monday. They issued a “buy” rating and a $34.00 target price for the company. Wall Street Zen upgraded shares of Septerna from a “sell” rating to a “buy” rating in a report on Sunday, November 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $31.00.

Septerna Price Performance

The company has a market capitalization of $1.33 billion, a price-to-earnings ratio of -19.69 and a beta of 3.80. The firm has a 50-day moving average price of $23.63 and a two-hundred day moving average price of $16.74.

Septerna (NASDAQ:SEPN) last announced its earnings results on Monday, November 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%. The firm had revenue of $21.50 million during the quarter, compared to analyst estimates of $24.50 million. On average, equities analysts predict that Septerna, Inc. will post -7.11 EPS for the current year.

Insider Activity at Septerna

In related news, SVP Daniel D. Long sold 3,501 shares of the stock in a transaction on Monday, November 10th. The shares were sold at an average price of $18.06, for a total transaction of $63,228.06. Following the completion of the transaction, the senior vice president owned 92,911 shares in the company, valued at approximately $1,677,972.66. This represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Septerna

Large investors have recently modified their holdings of the business. BVF Inc. IL increased its position in shares of Septerna by 79.3% in the first quarter. BVF Inc. IL now owns 4,396,124 shares of the company’s stock valued at $25,454,000 after acquiring an additional 1,944,100 shares during the last quarter. Checkpoint Capital L.P. bought a new position in Septerna in the first quarter valued at approximately $4,776,000. ADAR1 Capital Management LLC acquired a new position in shares of Septerna during the 1st quarter worth approximately $4,174,000. Perceptive Advisors LLC bought a new stake in shares of Septerna during the 2nd quarter worth approximately $5,723,000. Finally, VR Adviser LLC bought a new stake in shares of Septerna during the 2nd quarter worth approximately $5,713,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.